|
Multiple Sites
|
|
Protocol#
|
Principal Investigator
|
Title
|
| UCI 07-03 |
Sanati |
Determining the Utility of an Assessment Tool for Older Patients with Cancer |
UCI 06-23 |
Holcombe |
A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients with Cancer
(on hold) |
| UCI 98-20 |
Holcombe |
Investigation Into the Molecular Events Involved in the Development of Cancer |
| UCI 02-38 |
Nelson |
Evaluation of Proteasomal Subunit Expression and Localization in Normal and Neoplastic Tissues |
| UCI 02-29 |
Holcombe |
Expression Patterns of Wnt-Related Genes in Cancer |
| UCI 02-22 |
Nelson |
Studies of Monocyte-Derived Dendritic Cell Biology; Application to Anti-tumor |
| UCI 02-14 |
Gu |
GeneBank Generic Research Protocol: Cancer Tissue and PeripheralWhole Blood. The Discovery and Evaluation of Biomarkers for the Prediction, Diagnosis and Management of Disease Protocol #GBG01 |
| UCI 03-39 |
Samoszuk |
Eosinophil-Fibroblast-Tumor Cell Interaction |
| UCI 03-74 |
Sommers |
The Quality of Life Consequences of Chemotherapy Induced Nausea and Vomiting |
| UCI 03-25 |
Samoszuk |
Mast Cell Tryptase in Human Cancer |
UCI 01-32 |
Lipkin |
A Staged Strategy for Virus Identification and Discovery |
| UCI 00-54 |
Forthal |
Protective Immune Responses in Cancer and Infectious Disease |
| GOG 136 |
Burger |
Acquisition of Human Ovarian and Other Tissue Specimens and Seruni to be used in study the Causes, Diagnosis, Prevention, and Treatment of Cancer (M.L. Cibull). Patients with stages III and IV papillary serous ovarian cancer not entered onto a GOG phase III study are ineligible. Patients must be entered within 6 wks of surgery
|
For additional information on open UCI clinical trials please call toll-free 1-877-UC-STUDY or email ucstudy@uci.edu.
